IL21 Pre-design Chimera RNAi
- Known as:
- IL21 Pre-design Chimera RNAi
- Catalog number:
- H00059067-R01
- Product Quantity:
- 10 nmol
- Category:
- -
- Supplier:
- Abno
- Gene target:
- IL21 Pre-design Chimera RNAi
Related genes to: IL21 Pre-design Chimera RNAi
- Gene:
- IL21 NIH gene
- Name:
- interleukin 21
- Previous symbol:
- -
- Synonyms:
- Za11, IL-21
- Chromosome:
- 4q27
- Locus Type:
- gene with protein product
- Date approved:
- 2000-03-29
- Date modifiied:
- 2019-04-23
Related products to: IL21 Pre-design Chimera RNAi
Related articles to: IL21 Pre-design Chimera RNAi
- Cytokines can elicit potent antitumor immunity, but their clinical use is often limited by systemic immune activation and dose-limiting toxicity. Protease-responsive masking offers a way to improve selectivity by linking cytokine activity to disease-associated protease cleavage, but current approaches have faced several challenges. Here we describe a de novo protein design strategy for generating protease-activatable cytokine prodrugs that overcomes these challenges. We use this strategy to design and characterize cytokine prodrugs and well-behaved AND-gated split systems that require both target-dependent colocalization and proteolytic unmasking to generate active cytokines. In challenging syngeneic tumor models, our IL-21 prodrugs reduced treatment-associated toxicity while maintaining antitumor efficacy. - Source: PubMed
Publication date: 2026/09/22
Shin HojeongTello Julissa GKim Chan JohngChun Jung-HoPeprah FrankParent Brendan DAtajanova TavusMahmud Robiah Arefin IbnQiang LiAguirre Andrew JDougan Stephanie KDougan MichaelBaker David - Arsenic (As) is an extremely hazardous trace metalloid frequently found in water bodies, where it poses substantial threats to all living organisms, including fish. Its removal has therefore become a significant global challenge. - Source: PubMed
Publication date: 2026/09/30
Habotta Ola ARawan Ahmad FAbdelmoneim DoaaAdly Mina SAteya AhmedIbrahim ImanAmer ShroukAzab Rasha EHabak SaraMorsi RehabHetta Helal FIbrahim Samah FShukry MustafaEl-Nemr AhmedRaia AmrAbdeen Ahmed - This study aimed to characterize the distributions of Th17 and regulatory T (Treg) cells and the associated interleukin-21 (IL-21) signaling in patients with human immunodeficiency virus (HIV) and Mycobacterium tuberculosis (Mtb) coinfection. - Source: PubMed
Publication date: 2026/09/25
Chen GaoChen Shikai - Hepatocellular carcinoma (HCC) remains a significant global health threat characterized by aggressive progression and high mortality rates. Despite therapeutic advancements, survival for advanced stages is unacceptably low, necessitating innovative approaches like Natural Killer (NK) cell-based immunotherapy. NK cells are crucial innate immune components providing rapid tumor cytotoxicity without prior sensitization. However, the HCC tumor microenvironment (TME) presents a formidable barrier, inducing NK cell dysfunction through immunosuppressive cytokines like TGF-[Formula: see text], chronic hypoxia, and metabolic exhaustion driven by lipid accumulation. This literature review consolidates and integrates findings regarding current NK cell-based strategies in HCC, with particular emphasis on mechanisms of NK cell dysfunction within the TME and therapeutic approaches designed to restore their antitumor activity. Emerging therapeutic strategies involve cytokine-supported approaches, including the adoptive transfer of autologous or allogeneic NK cells expanded ex vivo using stimuli such as IL-15 and IL-21. In parallel, advances in genetic engineering have enabled the development of modified NK cells, including chimeric antigen receptor (CAR)-NK platforms targeting HCC-associated antigens such as glypican-3 (GPC3) and CD147 and bispecific and trispecific killer cell engagers (BiKEs and TriKEs). This review underscores the translational potential of NK cell-based therapies by highlighting unresolved knowledge gaps in the complex interplay between NK cells and the TME. These developments provide a foundation for optimizing NK cell immunotherapy and improving prognostic outcomes for patients with HCC. - Source: PubMed
Publication date: 2026/09/24
Widowati WahyuWargasetia Teresa LilianaSadri BaharehNainggolan Ita MargarethaAzis RizalRifana Safira DindaRismani ElhamVosough Massoud - Precision-cut lymph node slices (PCLNS) provide a physiologically relevant ex vivo model to investigate lymphoid immune activation and vaccine adjuvant function while preserving native tissue architecture. In this study, we established for the first time porcine PCLNS and assessed the immunostimulatory capacity of PCLNS to Toll-like receptor (TLR) 7/8 agonist (Resiquimod; R848) alone or in combination with porcine circovirus type 2 (PCV2) or PCV2 virus-like particles (VLPs). - Source: PubMed
Publication date: 2026/09/09
Deosthali SamruddhiMarti-Garcia BernatHarris HeatherWerling NatalieNoad RobertGerner WilhelmWerling Dirk